Windtree Therapeutics Inc
WINT- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946486
No open-market purchases or sales by Windtree Therapeutics Inc insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Windtree Therapeutics Inc as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 5
- −10 vs. Q4 2024
- Shares held
- 45.3K
- −268.4K (−85.6%) vs. Q4 2024
- Total value
- $57.0K
- −$51.7K (−47.5%) vs. Q4 2024
- New holders
- 1
- 1 more added
- Sold out
- 11
- 3 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting WINT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 5 | $8.75K |
| Q1 2025 | 5 | $57.0K |
| Q4 2024 | 15 | $108.7K |
| Q3 2024 | 8 | $389.7K |
| Q2 2024 | 5 | $4.87K |
| Q1 2024 | 9 | $238.8K |
| Q4 2023 | 12 | $194.1K |
| Q3 2023 | 12 | $197.7K |
| Q2 2023 | 12 | $151.7K |
| Q1 2023 | 9 | $12.8K |
| Q4 2022 | 27 | $276.6K |
| Q3 2022 | 27 | $518.7K |
| Q2 2022 | 25 | $664.4K |
| Q1 2022 | 27 | $1.76M |
| Q4 2021 | 26 | $2.72M |
| Q3 2021 | 19 | $3.02M |
| Q2 2021 | 27 | $3.94M |
| Q1 2021 | 21 | $2.72M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Windtree Therapeutics Inc; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 28,765 | $36.2K | 0.00% | −30,846−51.7% | Reduced |
| Morgan Stanley | 15,000 | $18.9K | 0.00% | +15,000 | New |
| Tower Research Capital LLC (TRC) | 1,376 | $1.73K | 0.00% | −3,145−69.6% | Reduced |
| Bank of America Corp | 100 | $126 | 0.00% | +30+42.9% | Added |
| SBI Securities Co., Ltd. | 24 | $30 | 0.00% | −38−61.3% | Reduced |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −119,266−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −59,167−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −19,456−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −14,449−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −13,696−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −12,326−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −11,057−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Activest Wealth Management | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −2−100.0% | Sold out |